Cancer remains one of the most difficult diagnoses a patient and their family can receive. Despite the significant progress made in cancer therapy, some of the most prevalent cancers in Asia, including stomach, liver and colorectal cancer, remain the most challenging to treat.

With operations in Singapore and Shanghai, Hummingbird Bioscience focuses on the discovery and early development of oncology drugs, from pre-clinical target validation through to proof-of-concept (Phase II clinical trials).

Building on advances in systems and computational biology, and deep expertise in this domain, Hummingbird Bioscience seeks to mitigate the risks inherent in drug development while tackling some of the most difficult areas of oncology.

Key assets:

  • Advanced platform technology for rational design and development of therapeutic antibodies
  • Novel drug discovery algorithms and deep learning applied to whole genome datasets
  • Pipeline of projects against novel targets for gastric and liver cancer

INNOVATION

monoclonal antibody design

Advances in computational and structural biology coupled with access to manifold omics data sets allow Hummingbird Bioscience to identify and rapidly develop new potential therapeutics for important cancer targets.